Latest News for: 10 nsi

Edit

Medartis delivers 12% core sales growth in 2024 and improves its core EBITDA margin from 17% to 19%

Pharmiweb 18 Mar 2025
(10.8) ... Additionally, the NSI contract manufacturing business is classified as non-strategic and therefore excluded from core sales calculations ... -10.8% ... 1 Core growth excluding the NSI contract manufacturing business ... 10.5% ... 10.5%.
  • 1
×